Multiplexed Opportunity Siloam is expanding from single-analyte immunoassays to multiplexed automated desktop systems under a National Cancer Institute contract, presenting a potential selling point for integrated assay platforms and high-throughput diagnostics teams.

Point-of-Care Growth TROVA, a single-patient desktop system for point-of-care use, highlights a strategy to address rapid decentralized testing markets; sales discussions can target clinics, urgent care, and specialty practices needing fast, accurate results.

Low-Volume Advantage Optimiser platforms are designed for ultra-low volume, cost-effective testing, appealing to labs and startups seeking cost-efficient workflows, potential upsell to existing customers needing scalable, easy-to-use immunoassays.

Robust Platform With over seventy assays developed on the Optimiser platform, the system’s robustness and universality can be leveraged to cross-sell additional assays, integration with existing robotic automation, and maintenance contracts.

Strategic Flexibility The company is exploring strategic alternatives, presenting an opening for collaboration, investment, or acquisition discussions with larger diagnostics players focused on immunoassay platforms, precision medicine, and in vitro diagnostics expansion.